Drugs / G-CSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01875237 Background | Dec 2013 → Mar 2017 | leukemia, myeloproliferative neoplasm, plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01875237 ↗ |
| Route | Subcutaneous | “5 mcg/kg/day subcutaneously beginning on Day +7” NCT01875237 ↗ |